Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CGEM Stock Forecast 2026-2027
$13.95
Current Price
$796.64M
Market Cap
Buy 12
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CGEM Price Targets
+172.4%
To High Target of $38.00
+115.1%
To Median Target of $30.00
+72.0%
To Low Target of $24.00
CGEM Price Momentum
-11.4%
1 Week Change
+20.4%
1 Month Change
+56.4%
1 Year Change
+34.8%
Year-to-Date Change
-16.7%
From 52W High of $16.74
+145.6%
From 52W Low of $5.68
📊 TOP ANALYST CALLS
Did CGEM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cullinan is one of their latest high-conviction picks.
Latest CGEM Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, CGEM has a bullish consensus with a median price target of $30.00 (ranging from $24.00 to $38.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $13.95, the median forecast implies a 115.1% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Julian Harrison at BTIG, projecting a 172.4% upside. Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 72.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CGEM Analyst Ratings
12
Buy
0
Hold
0
Sell
CGEM Price Target Range
Low
$24.00
Average
$30.00
High
$38.00
Current: $13.95
Latest CGEM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CGEM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2026 | Wedbush | Robert Driscoll | Outperform | Maintains | $36.00 |
| Feb 17, 2026 | Citigroup | Samantha Semenkow | Buy | Initiates | $33.00 |
| Feb 2, 2026 | Guggenheim | Brad Canino | Buy | Initiates | $30.00 |
| Jan 8, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $27.00 |
| Dec 9, 2025 | Wedbush | Robert Driscoll | Outperform | Maintains | $34.00 |
| Nov 24, 2025 | BTIG | Julian Harrison | Buy | Maintains | $38.00 |
| Nov 20, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $26.00 |
| Sep 12, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $24.00 |
| Sep 10, 2025 | BTIG | Julian Harrison | Buy | Reiterates | $32.00 |
| Aug 21, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Assumes | $24.00 |
| Aug 18, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $28.00 |
| Jun 11, 2025 | Stifel | Alex Thompson | Buy | Reinstates | $22.00 |
| May 12, 2025 | UBS | David Dai | Buy | Maintains | $24.00 |
| Apr 16, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $33.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $35.00 |
| Feb 28, 2025 | Stifel | Buy | Maintains | $N/A | |
| Feb 28, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $33.00 |
| Jan 29, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $33.00 |
| Oct 24, 2024 | UBS | David Dai | Buy | Initiates | $30.00 |
| Oct 16, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $28.00 |
Cullinan Therapeutics, Inc. (CGEM) Competitors
The following stocks are similar to Cullinan based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cullinan Therapeutics, Inc. (CGEM) Financial Data
Cullinan Therapeutics, Inc. has a market capitalization of $796.64M with a P/E ratio of 9.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -44.0%.
Valuation Metrics
Market Cap
$796.64M
Enterprise Value
$468.52M
P/E Ratio
9.0x
PEG Ratio
0.8x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+44.8%
Current Ratio
10.2x
Debt/Equity
0.7x
ROE
-44.0%
ROA
-28.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cullinan Therapeutics, Inc. (CGEM) Business Model
About Cullinan Therapeutics, Inc.
What They Do
Develops targeted therapies for cancer treatment.
Business Model
Cullinan Therapeutics Inc. operates as an early-stage biopharmaceutical company that generates revenue by developing and commercializing innovative cancer therapies. The company focuses on immuno-oncology and precision medicine, creating a diverse pipeline of drug candidates targeting specific mutations and tumor mechanisms, which allows it to address unmet medical needs in various cancer types.
Additional Information
The company is positioned within the biotechnology and healthcare sectors, emphasizing its role in advancing cancer treatments. Its strategic approach in drug development not only showcases its commitment to innovation but also enhances its relevance in the growing market for targeted cancer therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
111
CEO
Mr. Nadim Ahmed
Country
United States
IPO Year
2021
Website
cullinantherapeutics.comCullinan Therapeutics, Inc. (CGEM) Latest News & Analysis
Latest News
Quick Summary
Cullinan Therapeutics reports initial data for CLN-978 in SLE and RA due Q2 2026, with cash of $439M as of Dec 31, 2025, providing a runway into 2029. NDA submission for Zipalertinib completed.
Why It Matters
Clinical data timelines and cash reserves indicate Cullinan Therapeutics is well-positioned for future developments, which could enhance its valuation and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) will participate in upcoming investor conferences, featuring CEO Nadim Ahmed and Dr. Jeffrey Jones. The company focuses on therapies for autoimmune diseases and cancer.
Why It Matters
Cullinan Therapeutics' participation in key investor conferences signals potential updates on their pipeline, influencing investor sentiment and stock performance in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cullinan Therapeutics is rated a Buy, supported by a strong T-cell engager pipeline, solid management, and over $430M in cash. CLN-049 shows ~30% CR rates in AML with a promising regulatory path.
Why It Matters
Cullinan Therapeutics’ strong cash position, promising drug pipeline, and favorable clinical results enhance its market potential, making it an appealing investment opportunity in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Positive
Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
22 days ago
Quick Summary
Cullinan Therapeutics, Inc. (CGEM) presented at Citi's 2026 Virtual Oncology Leadership Summit, providing insights into their oncology developments and strategic direction.
Why It Matters
Cullinan Therapeutics’ presentation may indicate progress in oncology developments, impacting stock performance and investor sentiment related to biotech innovation and market positioning.
Source: Seeking Alpha
Market Sentiment:
Neutral
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
23 days ago
Quick Summary
Cullinan Therapeutics, Inc. announced leadership details, including CEO Nadim Ahmed and Dr. Jeffrey Jones, on Feb. 18, 2026, focusing on therapies for autoimmune diseases and cancer.
Why It Matters
Cullinan Therapeutics' leadership announcement signals potential strategic shifts or advancements in their clinical pipeline, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced leadership details, with CEO Nadim Ahmed and Dr. Jeffrey Jones involved in advancing therapies for autoimmune diseases and cancer.
Why It Matters
Cullinan Therapeutics’ leadership announcement could signal strategic shifts or innovations, affecting investor confidence and stock performance in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CGEM Stock
What is Cullinan Therapeutics, Inc.'s (CGEM) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Cullinan Therapeutics, Inc. (CGEM) has a median price target of $30.00. The highest price target is $38.00 and the lowest is $24.00.
Is CGEM stock a good investment in 2026?
According to current analyst ratings, CGEM has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CGEM stock?
Wall Street analysts predict CGEM stock could reach $30.00 in the next 12 months. This represents a 115.1% increase from the current price of $13.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cullinan Therapeutics, Inc.'s business model?
Cullinan Therapeutics Inc. operates as an early-stage biopharmaceutical company that generates revenue by developing and commercializing innovative cancer therapies. The company focuses on immuno-oncology and precision medicine, creating a diverse pipeline of drug candidates targeting specific mutations and tumor mechanisms, which allows it to address unmet medical needs in various cancer types.
What is the highest forecasted price for CGEM Cullinan Therapeutics, Inc.?
The highest price target for CGEM is $38.00 from Julian Harrison at BTIG, which represents a 172.4% increase from the current price of $13.95.
What is the lowest forecasted price for CGEM Cullinan Therapeutics, Inc.?
The lowest price target for CGEM is $24.00 from Robert Burns at HC Wainwright & Co., which represents a 72.0% increase from the current price of $13.95.
What is the overall CGEM consensus from analysts for Cullinan Therapeutics, Inc.?
The overall analyst consensus for CGEM is bullish. Out of 16 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are CGEM stock price projections?
Stock price projections, including those for Cullinan Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 10:24 PM UTC